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RESEARCH ARTICLE Open Access
Targeted sequencing of circulating cell-free
DNA in stage II-III resectable oesophageal
squamous cell carcinoma patients
Pei Meng1,2†, Jiacong Wei1,3†, Yiqun Geng1†, Shaobin Chen4, Miente Martijn Terpstra3, Qiongyi Huang1,
Qian Zhang1, Zuoqing Su1, Wanchun Yu1, Min Su5, Klaas Kok3, Anke van den Berg2 and Jiang Gu1,6*
Abstract
Background: The aim of this study was to investigate the potential of cell-free DNA (cfDNA) as a disease biomarker
in oesophageal squamous cell carcinoma (ESCC) that can be used for treatment response evaluation and early
detection of tumour recurrence.
Methods: Matched tumour tissue, pre- and post-surgery plasma and WBCs obtained from 17 ESCC patients were
sequenced using a panel of 483 cancer-related genes.
Results: Somatic mutations were detected in 14 of 17 tumour tissues. Putative harmful mutations were observed in
genes involved in well-known cancer-related pathways, including PI3K-Akt/mTOR signalling, Proteoglycans in
cancer, FoxO signalling, Jak-STAT signalling, Chemokine signalling and Focal adhesion. Forty-six somatic mutations
were found in pre-surgery cfDNA in 8 of 12 patients, with mutant allele frequencies (MAF) ranging from 0.24 to
4.91%. Three of the 8 patients with detectable circulating tumour DNA (ctDNA) had stage IIA disease, whereas the
others had stage IIB-IIIB disease. Post-surgery cfDNA somatic mutations were detected in only 2 of 14 patients, with
mutant allele frequencies of 0.28 and 0.36%. All other somatic mutations were undetectable in post-surgery cfDNA,
even in samples collected within 3–4 h after surgery.
Conclusion: Our study shows that somatic mutations can be detected in pre-surgery cfDNA in stage IIA to IIIB
patients, and at a lower frequency in post-surgery cfDNA. This indicates that cfDNA could potentially be used to
monitor disease load, even in low disease-stage patients.
Keywords: Oesophageal squamous cell carcinoma, Circulating cell-free DNA, Next-generation sequencing
Background
Oesophageal squamous cell carcinoma (ESCC) is the most
common form of oesophageal cancer and is one of the
deadliest cancers worldwide [1]. Because early-stage
oesophageal cancer is mostly asymptomatic, the majority
of ESCC patients are diagnosed with advanced disease.
Despite improvements in imaging, surgical techniques and
chemoradiation therapy, effective treatment of ESCC pa-
tients remains challenging, with an overall 5-year survival
of less than 30% [1]. For localized ESCC, surgery is the
preferred option. However, even after radical resection,
the 5-year overall survival of ESCC patients with positive
lymph nodes is less than 40% [2, 3]. Moreover, the recur-
rence rate is also high in patients without positive lymph
nodes [4]. Thus, accurate and timely detection of minimal
residual disease or relapse is crucial for tailoring adjuvant
therapy for a longer survival time.
Liquid biopsies have become a research hotspot for
non-invasive follow-up on disease load and therapy re-
sponse and for early detection of recurrence [5]. Thus
far, promising results have been obtained with circulat-
ing cell-free DNA (cfDNA) [6–8]. PCR-based techniques
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such as droplet digital PCR (ddPCR) and PNA-medi-
ated PCR have been used to detect recurrent muta-
tions in EGFR and KRAS in lung cancer patients [9–
12] and in APC in colorectal cancer [13]. Although
the results are promising, these approaches require
prior knowledge of the mutations present in the
tumour sample. To circumvent this limitation, next
generation sequencing (NGS)-based approaches using
cancer hotspot panels or whole exome approaches
have been applied to cfDNA. These studies have re-
ported variable dynamic patterns in mutant allele fre-
quencies of somatic mutations in lung cancer, breast
cancer and colon cancer patients [7, 14–18]. Some
studies have been carried out to monitor treatment
response and disease progression by screening cfDNA
samples for mutations detected in the primary
tumour [5, 7]. For example, in stage II colon cancer
patients, the presence of tumour DNA in cfDNA pro-
vided evidence of minimal residual disease and was
associated with a higher risk of recurrence [7].
Only a few studies have focused on the analysis of
cfDNA in ESCC. The amount of cfDNA was shown to
be higher in ESCC patients compared to healthy controls
[19]. Three to 6 months after tumour resection, the
amount of cfDNA was significantly reduced, indicating
that a major fraction of the cfDNA is derived from
tumour cells. Another study showed the feasibility of
using cfDNA before and after surgery to track tumour
load [20]. Decreased mutant allele frequencies were gen-
erally observed in post-surgery plasma of 8 ESCC pa-
tients using whole exome sequencing and in 3 patients
using targeted deep sequencing.
Together, these studies have indicated that circulating
tumour DNA (ctDNA) can be detected in the cfDNA of
ESCC patients, but additional studies are required before
ctDNA can be used in routine clinical practice. In this
study, we carried out targeted deep-sequencing using a
cancer-related gene panel to explore the cfDNA muta-




Seventeen ESCC patients who underwent radical tumour
resection between November 1, 2013 and May 31, 2014
were included from the Shantou University cancer hos-
pital (Fig. 1). None of the patients were treated with
chemotherapy or radiotherapy before surgery. Tumour
tissue samples were stored at − 80 °C and evaluated by
proficient pathologists. Blood was collected 1 day before
surgery and between 3 to 4 h up to 9 days after surgery.
Clinical annotations were retrospectively extracted from
the institutional clinical database.
Blood sample separation
Whole blood (2-5 ml) samples were collected in EDTA
tubes and processed within 2 h. After centrifugation at
900×g for 10 min, whole blood samples were separated
into plasma and WBC fraction. Aliquots of plasma were
subjected to two subsequent centrifugation steps at 16,
000×g for 10 min at 4 °C to remove residual WBCs. Red
blood cells in the WBC fraction were lysed using stand-
ard procedures. WBCs were collected by centrifugation
at 600×g for 10 min and washed with PBS. All samples
were stored at − 80 °C.
DNA extraction, library preparation and sequencing
DNA isolations, library preparations and NGS of fresh
frozen tumour tissues, WBCs and plasma samples were
performed by Novogene (Beijing, China). In brief, the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) was
Fig. 1 Schematic representation of the sample collection and a brief summary of the sequencing results
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used to extract DNA from fresh frozen tumour tissues.
The QIAamp circulating nucleic acid kit (Qiagen) was
used to isolate cfDNA from 1 to 3ml of plasma. Gen-
omic DNA of WBCs was extracted using the RelaxGene
Blood DNA System (TianGen Biotech Co., Ltd., Beijing,
China). All DNA samples were analysed using Nanodrop
for purity (ratio of OD260/280) and DNA yield was
quantified using the Qubit dsDNA HS assay kit on the
Qubit 2.0 system (Life Technologies, Carlsbad, CA).
DNA samples were stored at − 80 °C until they were
subjected to NGS.
DNA input for sequencing was 500 ng for tissue sam-
ples and WBCs and about 30 ng for cfDNA samples.
Exons of 483 human protein-coding genes related to
cancer were included in the NGS panel designed by
Novogene [21] (Additional file 1). DNA fragments were
captured using Agilent SureSelect XT (Agilent, Santa
Clara, CA, USA). Paired-end 150 bp reads were gener-
ated on a Hiseq2500 sequencing system (Illumina,
Beijing, China).
Data analysis
FASTQ files were obtained from the company and proc-
essed as previously described [22]. Briefly, reads were
aligned to the hg19 reference genome with Burrows-
Wheeler Aligner (BWA) and Genome Analysis Toolkit
(GATK) [23]. Format conversion and de-duplication was
performed using Picard Tools. HaplotypeCaller was used
for variant calling in all samples in one workflow. The
data analysis pipeline is set to report all variants with a
MAF > 1%. Subsequently the pipeline reports the allele
depth for these variants in all samples. Personal variants
were filtered out when detected in the WBC samples at
a variant allele frequency of > 0.5% in combination with
a minimal variant allele count of two. In addition, we re-
moved all variants with a sequencing depth less than
25x in WBCs, because we cannot reliably assess whether
these represent personal variants or somatic mutations.
Variants with a coverage of <100x or a mutant allele fre-
quency (MAF) of < 5% in the primary tumour samples
were excluded, as these variants are likely to be present
in a minor subclone of the tumour. All other variants
observed in the tumour samples were considered to rep-
resent somatic mutations. For all somatic mutations
called in the tumour, mutations in cfDNA were deter-
mined to be present when we observed either (1) 4 al-
tered reads with a MAF > 0.5%, or (2) > 4 altered reads
and a MAF above the sequencing error background fre-
quency, which was 0.43% per position and 0.14% per al-
ternative nucleotide. Somatic mutations specific for
cfDNA, were reported when MAF > 1% and coverage>
100. As the background rate for INDELs is much lower,
we considered INDELs with two or more altered reads
as true somatic mutations, irrespective of the MAF.
To further establish the reliability of the mutations re-
ported in cfDNA in our study, we checked the read
counts of the non-REF and non-variant bases by IGV.
This indicates the sequencing error rate at this specific
site. Prediction of pathogenicity of somatic variants was
based on Combined Annotation Dependent Depletion
(CADD) score [24]. We defined variants with a CADD
score ≥ 20 as harmful. For the analyses of the mutational
profile in tumour tissues, including the downstream
pathway analysis, we focused on putative harmful muta-
tions. DAVID v6.8 [25] was used for KEGG pathway
analysis of the genes with harmful mutations. For the
analyses of cfDNA, we included all somatic mutations,
including non-harmful and silent mutations, as these
can be equally informative for disease load.
Statistics
For non-normally distributed data sets, median and
range are given, and significance was determined by
Mann-Whitney-Wilcoxon rank sum test. A P-value <
0.05 was considered significant.
Results
Patient characteristics
Characteristics of the ESCC patients are shown in Add-
itional file 2. The cohort of 17 patients consisted of 12
males and 5 females (age range from 42 to 77 years), all di-
agnosed with stage II to III disease. All patients were
followed-up for 24months. Four of the 17 patients experi-
enced disease progression at 4 to 21months after surgery.
For 2 of the 4 patients with progression, the amount of
cfDNA in the pre-surgery plasma sample was too low for
NGS analysis. Median cfDNA yield was 11.9 ng (range
4.86–38.6 ng) per ml of plasma. The amount of plasma
cfDNA obtained before surgery was lower than after sur-
gery (p = 0.015) (Fig. 2). No obvious differences in cfDNA
yield were seen between samples obtained 3–4 h after sur-
gery compared to those obtained 2–9 days after surgery.
Overview of NGS results
A summary of the sequencing data is shown in Add-
itional file 3. A phred quality score of 30 (Q30) was
achieved for 91% of the bases. Mean target coverage of
all samples was 667x and more than 95% of the target
bases reached a coverage of more than 100x. The aver-
age mismatch rate per nucleotide position was 0.14% per
base. Additional file 4 gives an overview of the somatic
mutations detected per sample and per patient. No som-
atic mutations were detected in the tumour samples of
three of the patients, nor in their corresponding pre-
and post-surgery cfDNA samples. We therefore excluded
these three patients from further analysis.
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Somatic mutations in tumour DNA
We detected a total of 131 somatic mutations with a
median coverage of 348x (range 100x to 3131x)
(Additional file 4). Sixty-three of the 131 (48.1%)
had a CADD score > 20, indicating a putatively
pathogenic effect. The median number of mutations
per patient was 9 (range 2 to 17) and the median
MAF was 21.0% (range 9.7 to 85.2%). TP53 was the
most commonly mutated gene, with pathogenic mu-
tations in 14 patients, followed by mutations in
NOTCH1 (4 patients), CDKN2A (3 patients), KMT2C
(2 patients) and PTEN (2 patients) (Table 1). Two
recurrent mutations were observed one in TP53 and
one in CDKN2A. Pathway analysis of the 37 genes
with harmful mutations indicated a total of 30 sig-
nificantly enriched pathways (p-value < 0.01), each
encompassing 4 to 9 mutated genes (Additional file 5).
These include the PI3K-Akt/mTOR (9 genes), FoxO
(7 genes), Jak-STAT (7 genes), Chemokine (7 genes)
and Focal adhesion (7 genes) signalling pathways and
the Proteoglycans in cancer (8 genes) pathway.
Somatic mutations in pre- and post-surgery cfDNA
Part of the mutations identified in tumour samples were
also identified in cfDNA. No novel mutations were
found in any of the patients including the 3 patients
without somatic mutations in the tumour. Five of the
patients had no detectable somatic mutations in pre-
and/or post-surgery cfDNA (Table 2). Seven patients
had somatic mutations pre-surgery, but not in post-sur-
gery cfDNA. One patient (ESCC14) had 4 mutations in
pre-surgery cfDNA and one mutation in post-surgery
cfDNA. The remaining patient (ESCC07) lacked pre-
surgery cfDNA, but did have one mutation in post-sur-
gery cfDNA. As a control for the reliability of our filter-
ing criteria, we analysed the sequencing error read at
mutant base positions of all mutations detected in the
tumour samples. In all cases this was less than 4 reads in
all cfDNA samples and below the MAF observed for the
cfDNA sample (Additional file 6).
The median number of mutations observed in pre-sur-
gery cfDNA was 5 per patient. For two patients, a high
proportion of the somatic mutations detected in the
tumour were also detected in pre-surgery cfDNA (80%
for both ESCC09 and ESCC10). The median on-target
coverage for the cfDNA samples was 613x (range 391x
to 839x) pre-surgery and 752x (range 546x to 1932x)
post-surgery. There was no difference in the coverage at
positions for which mutant reads were detected (median
673x, range 391x to 839x) as compared to positions for
which no mutant reads were detected (median 543x,
range 471x to 725x) in cfDNA (Fig. 3). The median mu-
tant allele frequency was 1.3% in pre-surgery cfDNA
(range 0.24 to 4.91%). For all somatic mutations, the
MAFs in pre-surgery cfDNA were much lower than
those observed in the tumour tissue (Fig. 4).
In 2 of the 14 post-surgery cfDNA samples, we
identified one of the somatic mutations observed in
the corresponding tumour tissue. In the remaining 12
post-surgery cfDNA samples, no mutations were ob-
served. Mutant allele frequencies of the two muta-
tions were 0.28% (ESCC07) and 0.36% (ESCC14). For
one patient the time between surgery and blood col-
lection was 3–4 h and for the second patient this was
6 days.
Correlation of cfDNA mutations with clinical
characteristics
We detected cfDNA mutations in pre-surgery samples
from 4 out of 6 stage II and 4 out of 6 stage III patients.
Only one of the three patients with disease recurrence
within 1 year had pre-surgery cfDNA. In this patient, 6
of the 12 somatic mutations observed in the correspond-
ing tumour DNA were detectable in cfDNA. For the
other two patients, we only had post-surgery cfDNA,
and in one of the two we detected a single mutation out
of three somatic mutations detected in the tumour
samples.
Discussion
Early detection of tumour recurrence and a tool to
evaluate treatment response in ESCC would allow us to
optimize treatment strategy for individual patients. In
the absence of effective prognostic biomarkers in ESCC
[26], analysis of cfDNA might provide an easily access-
ible source of information to monitor disease load after
surgery. In this study we performed targeted sequencing
Fig. 2 Cell-free DNA yield in pre- and post-surgery blood samples.
DNA yields were calculated per millilitre of blood. Sixteen pairs of
cfDNA samples were included as one of the two insufficient pre-
cfDNA samples information is not available. The amount of plasma
cfDNA isolated before surgery was lower than the amount obtained
after surgery (p = 0.015) based on Mann-Whitney-Wilcoxon rank
sum test
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of pre- and post-surgery cfDNA and of matched
tumour tissues and WBCs. Our main finding is that
we were able to detect a subset of the tumour-spe-
cific somatic mutations in pre-surgery cfDNA for
most of our stage II and stage III ESCC patients
using as little as 3 ml blood. Most of these mutations
were not detected in cfDNA of blood samples ob-
tained as early as 3–4 h after surgery.
Table 1 Overview of all recurrently mutated genes (mutated in at least 3 patients)
Gene Patient
ID





tumour DNA Pre-cfDNA Post-cfDNA WBC
TP53 ESCC01 c.1036G > T p.Glu346* 44 24.9% 2.2% – –
c.673-2A > G . 23 43.9% 2.3% – –
ESCC02 c.733G > A p.Gly245Ser 35 43.0% – – –
c.839G > C p.Arg280Thr 33 20.2% – – –
ESCC03 c.614A > G p.Tyr205Cys 24 73.7% – – –
ESCC04 c.223_229delCCTGCAC p.Pro75fs 20 76.1% 1.7% – –
ESCC05 c.364_365insT p.Thr123fs 35 85.2% – – –
ESCC06 c.551_554delATAG p.Asp184fs 33 10.7% – – –
ESCC07 c.920-1G > T . 25 14.4% NA – –
ESCC08 c.770_782 + 10delTGG
AAGACTCCAGGTCAGGAGCC
p.Leu257fs 33 18.3% 0.9% – –
ESCC09 c.643A > G p.Ser215Gly 29 29.3% 2.3% – –
ESCC10 c.481G > A p.Ala161Thr 27 66.2% 2.8% – –
ESCC11 c.844C > T p.Arg282Trp 33 27.1% NA – –
ESCC13 33 21.9% – – –
ESCC12 c.643A > C p.Ser215Arg 27 27.9% – – –
ESCC14 c.742C > T p.Arg248Trp 34 27.3% 0.9% – –
c.818G > A p.Arg273His 27 15.0% – – –
NOTCH1 ESCC01 c.4672dupG p.Leu1559fs 35 57.6% 4.9% – –
c.1070 T > C p.Phe357Ser 29 13.6% 2.1% – –
ESCC02 c.1359_1361delCAA p.Asn454del 19 62.7% – – –
ESCC05 c.867_868insC p.Gln290fs 29 83.2% – – –
ESCC08 c.928G > A p.Gly310Arg 27 26.8% 0.6% – –
ESCC09 c.4646G > T p.Cys1549Phe 29 27.6% 1.8% – –
KMT2D ESCC02 c.12823C > T p.Gln4275* 41 43.8% – – –
c.14119C > G p.Pro4707Ala 18 20.3% – – –
ESCC05 c.636delA . 1 30.4% – – –
ESCC08 c.9730delG p.Glu3244fs 35 13.5% – – –
KMT2C ESCC04 n.-1G > A . 6 19.5% – – –
ESCC11 c.569G > A p.Arg190Gln 24 15.2% NA – –
ESCC14 c.11953G > A p.Gly3985Arg 24 12.7% 0.6% 0.4% –
CDKN2A ESCC09 c.316 + 1G > T . 27 28.8% 2.6% – –
c.172C > T p.Arg58* 35 27.0% 1.8% – –
ESCC10 35 65.5% 1.4% – –
ESCC14 c.488G > A p.Arg163Gln 34 42.6% – – –
ETV6 ESCC01 c.329-72C > T . 4 21.1% – – –
ESCC04 c.464-2686G > C . 2 36.2% 0.6% – –
ESCC10 c.164-14646G > A . 2 20.3% 0.7% – –
* Nonsense
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Even though our study cohort size is limited, this is the
most extensive study thus far to compare pre- and post-sur-
gery cfDNA in stage II and III ESCC patients. For 3 of the
patients no somatic mutations were identified, despite the
use of a broad cancer gene panel consisting of 483 genes.
Thus, future studies should focus on a larger or ESCC-spe-
cific panel to allow detection of mutations in all patients.
Regretfully, due to lack of material we could not do
an independent validation of the mutations detected
in cfDNA. To overcome this shortcoming, we moni-
tored sequencing error rates for all positions for
which we identified mutations in cfDNA using our
predefined criteria. This indicated that the sequencing
errors did not pass our criteria. Moreover, in our pre-
vious NGS-based studies we validated close to 100%
of the mutations called in the NGS data by the same
pipeline for all variants with 4 or more reads by an
independent technique [27, 28]. Finally, our pipeline
for variant calling is based on the GATK workflow,
and this pipeline was previously shown to have a sen-
sitivity of 95% and positive predictive value of 99%
[29]. Taken together, we consider the mutations in
cfDNA as called in our study as reliable.
Previous studies have demonstrated that ctDNA can
be detected in most advanced-stage cancer patients
with high sensitivity. This allows monitoring of thera-
peutic response, identification of tumour-specific vari-
ants relevant for choice of therapy, and detection of
acquired resistance-induced mutations. Using ddPCR,
somatic mutations have been detected in cfDNA of
more than 75% of patients with advanced pancreatic,
ovarian, colorectal, bladder, gastroesophageal, breast,
melanoma, hepatocellular and head and neck cancers,
but in less than 50% of primary brain, renal, prostate
or thyroid cancers [18]. Thus, it is clear that the pres-
ence of ctDNA varies between cancer types. In our
study cohort, somatic mutations were found in pre-
surgery cfDNA in 8 out of 12 patients. Our data sup-
port the potential of using cfDNA as a biomarker of
disease load for this patient group for whom no ef-
fective biomarker is currently available. The detection
rate could be higher with optimized approaches for
detection of variants with low MAF and using an ex-
tended ESCC-specific gene panel.
A high-throughput sequencing approach allows de-
tection of somatic mutations in cfDNA in a more
comprehensive target region, as compared to muta-
tion-specific PCR approaches, albeit with a somewhat
lower sensitivity. With the detection of ctDNA in 4
out of 6 stage II patients, our results are comparable
to the findings in previous studies focusing on stage I
or II colorectal, breast, lung, ovarian and pancreatic
cancer, with 43 to 71% of patients harbouring somatic
mutations in cfDNA [17, 30]. This indicated the pres-
ence of ctDNA even under a low tumour burden. In
colorectal cancer a higher MAF in pre-operative
cfDNA has been associated with disease recurrence
and overall survival [17]. In our study, a stage IIA pa-
tient with a mean MAF of 2.4% in pre-surgery
cfDNA, but without any detectable mutations in post-











Number of somatic mutations
Tumour Pre-surgery Post-surgery
ESCC01 PT2N0M0G2–3 IIA 5 m N 2d 12 6 0
ESCC02 PT3N0M0G2 IIB N N 3-4 h 13 2 0
ESCC03 PT2N0M0G2 IIA N N 3-4 h 13 0 0
ESCC04 PT3N0M0G2 IIA N N 3-4 h 17 6 0
ESCC05 PT3N0M0G1 IIA N N 9d 9 1 0
ESCC06 PT3N0M0G2 IIA N N 5d 3 0 0
ESCC07 PT3N0M0G1 IIA 12 m Y 3-4 h 3 NA 1
ESCC08 PT3N1M0G1 IIIB N N 3-4 h 9 3 0
ESCC09 PT4aN0M0G2 IIIB N N 3-4 h 10 8 0
ESCC10 PT4aN0M0G2 IIIB N N 9d 20 16 0
ESCC11 PT3N1M0G3 IIIB 4 m N 3-4 h 5 NA 0
ESCC12 PT3N1M0G2 IIIB N Y 3-4 h 2 0 0
ESCC13 PT3N1M0G2 IIIB N Y 3-4 h 2 0 0
ESCC14 PT2N1M0G2 IIIA N Y 6d 13 4 1
PFS Progression-free survival, N no progression during follow-up, m months, CRT Chemoradiotherapy, NA Not Available
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surgery cfDNA, developed a recurrence 5 months
after surgery. Additional studies are needed to further
prove the potential clinical relevance of high MAF in
cfDNA.
Postoperative adjuvant chemoradiotherapy was
recommended to eliminate micrometastatic disease
and minimal residual disease. Unfortunately, there
is no effective tool to assess minimal residual dis-
ease for early tailoring of adjuvant therapy to avoid
both under- and overtreatment. In addition, there is
also no effective tool for early relapse surveillance
prior to imaging. Detection of ctDNA after resec-
tion can point to minimal residual disease or even
predict clinical relapse and poor outcome in differ-
ent cancer types [7, 30, 31]. Due to the limited
number of patients in our study and post-surgery
treatment in some of them, we cannot reliably as-
sess the potential clinical value of the presence of
ctDNA in pre- and post-surgery cfDNA. Neverthe-
less, we did observe timely changes in MAF in
cfDNA as early as 3 to 4 h after surgery, which is
consistent with the reported half-life of cfDNA ran-
ging from 16 min to 2 h [32, 33]. The relatively
short half-life of cfDNA makes it a good biomarker
to monitor dynamic changes in disease load.
Cellular damage due to the surgery may lead to an
increased amount of cfDNA, as we observed in
some post-surgery cases. This will lead to a frac-
tional decrease in the amount of ctDNA. Thus,
both cellular damage and the short half-life of
cfDNA may cause drop of the MAF to below the
detection limit. So for residual disease monitoring
is advisable to draw blood a few days after surgery.
Theoretically, ctDNA could be used broadly to
guide treatment and to monitor for treatment resist-
ance or cancer recurrence. CtDNA is also more
specific to tumour load compared to serum-based
protein biomarkers such as cancer antigen 125 in
ovarian cancer patients [16], and can be used for tu-
mours for which no serum-based protein biomarkers
are available, as is the case for ESCC [34].
Conclusion
We detected tumour-specific mutations in pre-sur-
gery cfDNA of both stage II and stage III ESCC pa-
tients. In samples taken shortly after surgery,
mutations were either undetectable or had a signifi-
cantly lower MAF, which indicates that the presence
of mutations in cfDNA correlates with tumour load.
Fig. 3 Coverage at the target regions in cfDNA samples. a) pre-surgery cfDNA samples. b) post-surgery cfDNA samples. Mean target region
coverage (black squares) and the coverage for the nucleotide positions for which somatic mutations were detected in the corresponding tumour
samples is indicated. Dot colours indicate coverage at the nucleotide position for which the mutant allele was (orange dots) or was not (green
dots) detected in cfDNA
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This implies that cfDNA may be used as a marker
for the presence of tumour cells in ESCC patients.
Larger studies are needed to establish the clinical
applicability of cfDNA and the predictive value of
treatment outcome as we only had three samples of
patients that relapsed after surgery.
Additional files
Additional file 1: Overview of the 483 genes present in the Illumina
cancer gene panel. (XLSX 14 kb)
Additional file 2: Clinical and pathological features of ESCC patients.
(XLSX 10 kb)
Additional file 3: Overview of the sequencing results. In this table,
paired read number, Q30, aligned read number, percentage of duplicate
reads, aligned unique read number and mean target coverage are listed
per sample. (XLSX 18 kb)
Additional file 4: Details of all somatic mutations. Coding sequence
mutations, amino acid changes, CADD score, ALT read counts and MAF
for tumour, pre-surgery plasma, post-surgery plasma, and WBC are listed.
(XLSX 42 kb)
Additional file 5: Overview of the pathway analysis by DAVID. All genes
with predictive pathogenic mutation were analysed through DAVID. The
table shows the KEGG pathways, genes in each pathway and p-values.
(XLSX 14 kb)
Additional file 6: Background sequencing errors. Background mutant
reads for each of 37 somatic SNVs (X-axes) are indicated by their absolute
read number (panel A) and by their allele frequency (Panel B).
Background variants are defined as the non-reference-specific and non-
tumour-specific nucleotide at the position of the SNVs. The nucleotide
variant with the highest read count is shown (in red) to illustrate the
mismatch error rate at the positions mutated in primary tumour samples.
All background variants (shown in red) were filtered out by our custom
filter criteria and all variants listed as true cfDNA mutations had read
counts well above these background levels (blue squares). (PDF 1561 kb)
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cfDNA: cell free DNA; ctDNA: circulating tumour DNA; ddPCR: droplet digital
PCR; EC: Oesophageal cancer; ESCC: Oesophageal squamous cell carcinoma;
MAF: Mutant allele frequency; NGS: Next generation sequencing
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